Abstract
Photodynamic therapy has many treatment applications for malignant and premalignant lesions of the skin. The basic principle involves application of a photosensitizer followed by exposure of the _target tissues to light. 5-aminolevulinic acid is a natural occurring compound in the heme biosynthesis pathway. Its metabolite protoporphyrin IX is a photosensitizer that has the ability to selectively damage premalignant, malignant, and certain abnormal tissues, rendering its wide application for use in actinic keratosis, Bowen’s disease, and basal cell carcinoma. Adequate lesion preparation is critical for successful treatment. Ongoing research on the clinical use of photodynamic therapy, its potential impact in oncological patient management and on public health and cost is continuously evolving. The perfection of this light therapy on patient treatment awaits results of future clinical trials.
Keywords: Non-melanoma, photodynamic therapy, photosensitizers, skin cancer, treatment.
Current Cancer Therapy Reviews
Title:Photodynamic Therapy: The Light Treatment for Cutaneous Non- Melanoma Malignancies
Volume: 12 Issue: 2
Author(s): Edward Yu
Affiliation:
Keywords: Non-melanoma, photodynamic therapy, photosensitizers, skin cancer, treatment.
Abstract: Photodynamic therapy has many treatment applications for malignant and premalignant lesions of the skin. The basic principle involves application of a photosensitizer followed by exposure of the _target tissues to light. 5-aminolevulinic acid is a natural occurring compound in the heme biosynthesis pathway. Its metabolite protoporphyrin IX is a photosensitizer that has the ability to selectively damage premalignant, malignant, and certain abnormal tissues, rendering its wide application for use in actinic keratosis, Bowen’s disease, and basal cell carcinoma. Adequate lesion preparation is critical for successful treatment. Ongoing research on the clinical use of photodynamic therapy, its potential impact in oncological patient management and on public health and cost is continuously evolving. The perfection of this light therapy on patient treatment awaits results of future clinical trials.
Export Options
About this article
Cite this article as:
Yu Edward, Photodynamic Therapy: The Light Treatment for Cutaneous Non- Melanoma Malignancies, Current Cancer Therapy Reviews 2016; 12 (2) . https://dx.doi.org/10.2174/1573394712666160919104726
DOI https://dx.doi.org/10.2174/1573394712666160919104726 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics
The thematic issue "Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics" aims to explore cutting-edge developments and innovative strategies in the field of lipid nanoparticle (LNP) technology, particularly focusing on its application in mRNA delivery. This topic has gained unprecedented attention and urgency in the wake of the COVID-19 ...read more
Current Progress in Protein Degradation and Cancer Therapy
_targeted Protein Degradation is gaining momentum in cancer therapy; it facilitates _targeting undruggable proteins, overcomes cancer resistance, and avoids undesirable side effects. Thus small molecule degraders have emerged as novel therapeutic strategies. _targeted protein degradation (TPD), the process of eliminating a protein of interest holds a great promise for the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Parallel Synthesis of “Click” Chalcones as Antitubulin Agents
Medicinal Chemistry Personalized Medicine for Glioblastoma: Current Challenges and Future Opportunities
Current Molecular Medicine Medium-Term Culture of Primary Oral Squamous Cell Carcinoma in a Three- Dimensional Model: Effects on Cell Survival Following Topical 5-Fluororacile Delivery by Drug-Loaded Matrix Tablets
Current Pharmaceutical Design Editorial (Thematic Issue: Advances in the Diagnosis and Treatment of Polycystic Ovarian Syndrome)
Current Pharmaceutical Design Plant-based Adjuvant in Vaccine Immunogenicity: A Review
Current Traditional Medicine The Role of Spiritual Health Experience with Intensity and Duration of Labor Pain While Childbearing and Postpartum
Current Women`s Health Reviews Antiplasmodial Activity and Some Active Compounds from Stachytarpheta cayennensis Vahl. (Verbenaceae) Leaf Fractions
Anti-Infective Agents Arginine Deprivation as a _targeted Therapy for Cancer
Current Pharmaceutical Design Dendritic Cell/NK Cell Interaction in RNA Virus Infection
Current Immunology Reviews (Discontinued) Radiolabeled Peptides for Molecular Imaging of Apoptosis
Current Medicinal Chemistry Anti-Angiogenic Drugs and Biomarkers in Non-Small-Cell Lung Cancer: 'A Hard Days Night'
Current Pharmaceutical Design Effects of Exosomes on Major Pathways Promote Tumor Formation and Progression
Current Molecular Medicine Decreased Vascular Repair and Neovascularization with Ageing: Mechanisms and Clinical Relevance with an Emphasis on Hypoxia- Inducible Factor-1
Current Molecular Medicine Light Deficiency Confers Breast Cancer Risk by Endocrine Disorders
Recent Patents on Anti-Cancer Drug Discovery Polyunsaturated Fatty Acids and Cardiovascular Disease
Current Pharmaceutical Design DNA Methylation and Bladder Cancer: Where Genotype does not Predict Phenotype
Current Genomics Inhibition of RET Activated Pathways: Novel Strategies for Therapeutic Intervention in Human Cancers
Current Pharmaceutical Design Phosphodiesterase Inhibitors as a _target for Cognition Enhancement in Aging and Alzheimer’s Disease: A Translational Overview
Current Pharmaceutical Design When Ubiquitin Meets NF-κB: A Trove for Anti-cancer Drug Development
Current Pharmaceutical Design The Proteins Interacting with Prmt5 in Medaka (Oryzias latipes) Identified by Yeast Two-Hybridization
Protein & Peptide Letters